Obesity Latest News: GLP-1 Pill Update, Discount Wars & Pharma Shakeups
In this week’s Obesity Updates, we’re diving into pivotal shifts transforming the obesity treatment landscape — from regulatory milestones to fierce market moves and emerging therapies.
Key updates include:
🌍 WHO endorses GLP-1 drugs like Wegovy and Ozempic for global use
💊 Novo Nordisk’s 25mg oral semaglutide moves closer to FDA approval
📉 Pfizer halts early obesity drugs, slashes $1.2B amid setbacks
🚀 Amgen’s MariTide shows strong Phase 2 results, up to $10B forecasted revenue
💰 Eli Lilly’s Zepbound and Mounjaro drive a 45% revenue jump in Q1 2025
🤝 Novo teams up with telehealth to offer Wegovy at $499/month
These updates reflect the fast-moving dynamics in obesity therapeutics, where oral GLP-1s, pricing strategies, and next-gen candidates are reshaping patient care and industry competition.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #GLP1 #PharmaNews #ClinicalTrials #HealthcareInnovation #LucidQuest #WeightLossScience #BiotechUpdates #Wegovy #Zepbound #NovoNordisk #EliLilly #Amgen #Pfizer #ObesityTreatment #HealthcareConsulting